Emerald Health Pharmaceuticals (EHP) is a clinical-stage biopharmaceutical company focused on developing a new class of proprietary molecules with unique capabilities that can potentially modify and reverse disease progression in patients suffering from devastating neurodegenerative and autoimmune diseases.
The company has created two families of new chemical entities. These molecules have been created through rational drug design to modulate specific receptors and physiological pathways in the body, which are validated targets in many serious diseases. With a multi-pronged mechanism of action (MOA), these NCEs are well positioned as first-in-class disease-modifying therapeutic drug candidates for many diseases, which currently have no cure.
Driven by eminent global researchers in science and biotechnology, EHP has assembled a highly experienced and expert management team, supported by clinical and scientific advisory boards, to successfully develop these pharmaceutical drug product candidates.